Kexing Biopharm Subsidiary Enrolls First Patient for Phase 1 Study for Growth Hormone Treatment
Kexing Biopharm Subsidiary Enrolls First Patient for Phase 1 Study for Growth Hormone Treatment
科興製藥子公司推出首個創業板生長激素治療第一階段研究的患者
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊